JW (Cayman) Therapeutics Co. Ltd. announced appointment of Mr. Min Liu as the Chief Executive Officer of the Company. Mr. Liu will lead the Group with a focus on innovation, strategic partnership, operational excellence, and creating long-term value for all stakeholders. Mr. Liu, aged 51, possesses over 25 years of experience in the pharmaceutical industry. Prior to joining the Group, from February 2018 to September 2022, he served as the chief
commercial officer of Innovent Biologics Inc., where during his tenure he helped build Innovent's commercial capabilities with a leading competitive commercialization organization in the market. He led the key successful launches of various innovative products, planned and executed the major market access strategy to establish market share leadership, and managed key partnership collaborations and reached major strategic deals. Before that, from October 2012 to January 2018, Mr. Liu served as a vice president at F. Hoffmann-La Roche Ltd. ("Roche") in the PRC, where he led the development of various business units, including one of the two oncology business units of Roche in the PRC. Earlier in his career, from 1995 to 2012, Mr. Liu also held managerial roles in a number of reputable multinational pharmaceutical companies. Mr. Liu obtained his master of business administration degree from Harvard Business School in the United States in June 2004. He received his bachelor's degree in biochemistry from Wuhan University in the PRC in June 1994. The Board is confident that Mr. Liu's comprehensive experience and in-depth industry knowledge will guide the Group towards achieving its new milestones. His appointment aligns with strategic goals and is expected to significantly benefit development, daily operations and management. Looking forward, the Group is poised to embrace future opportunities and challenges, aiming to enhance its leadership in the industry. The Board further announced that Dr. Yiping James Li, an Chief Executive Officer of the Company, has resigned from his role as the Chief Executive Officer of the Company with effect from July 31, 2024 to dedicate more time for his family and other personal interests.